Regeneron Pharmaceuticals REGN Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's deferred revenue?
- Regeneron Pharmaceuticals (REGN) reported deferred revenue of $636.2M in Q1 2026.
- How has Regeneron Pharmaceuticals's deferred revenue changed year-over-year?
- Regeneron Pharmaceuticals's deferred revenue increased by 2.7% year-over-year, from $619.3M to $636.2M.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's deferred revenue has grown at a -0.9% compound annual growth rate (CAGR), from $577.7M to $553M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.